Cardinal Health Given Average Rating of “Buy” by Analysts (NYSE:CAH)
Cardinal Health (NYSE:CAH) has been given a consensus recommendation of “Buy” by the nineteen ratings firms that are currently covering the stock, AR Network reports. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $77.93.
Shares of Cardinal Health (NYSE:CAH) opened at 73.0202 on Monday. Cardinal Health has a 52 week low of $49.65 and a 52 week high of $74.40. The stock’s 50-day moving average is $71.35 and its 200-day moving average is $69.68. The company has a market cap of $24.583 billion and a price-to-earnings ratio of 21.58.
Cardinal Health (NYSE:CAH) last released its earnings data on Monday, August 4th. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.81 by $0.02. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $21.88 billion. During the same quarter last year, the company posted $0.79 earnings per share. Cardinal Health’s revenue was down 9.9% compared to the same quarter last year. On average, analysts predict that Cardinal Health will post $4.25 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be paid a dividend of $0.3425 per share. This represents a $1.37 annualized dividend and a dividend yield of 1.88%. The ex-dividend date is Monday, September 29th.
In other Cardinal Health news, EVP Mark R. Blake sold 4,782 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $72.15, for a total value of $345,021.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Argus reiterated a “buy” rating on shares of Cardinal Health in a research note on Monday, August 18th. They now have a $71.43 price target on the stock, down previously from $83.00. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Cardinal Health in a research note on Tuesday, August 5th. They now have a $82.00 price target on the stock, up previously from $77.00. Finally, analysts at Credit Suisse reiterated an “outperform” rating on shares of Cardinal Health in a research note on Tuesday, August 5th. They now have a $80.00 price target on the stock, up previously from $76.00.
Cardinal Health, Inc is a healthcare services company providing pharmaceutical and medical products and services to pharmacies, hospitals, ambulatory surgery centers, clinical laboratories, physician offices and other healthcare providers.
Receive News & Ratings for Cardinal Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.